血液病理医としてスタートし、留学中は大腸がんの幹細胞の研究を行い、現在は胸部腫瘍、とくに肺癌の分子病理学的アプローチにより研究しています。診断病理医として、分子生物学を取り入れた新しい診断を目指しています。
- Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. Exp Hematol Oncol 11:82, 2022
-
Hamamoto R, Koyama T, Kouno N, Yasuda T, Yui S, Sudo K, Hirata M, Sunami K, Kubo T, Takasawa K, Takahashi S, Machino H, Kobayashi K, Asada K, Komatsu M, Kaneko S, Yatabe Y, Yamamoto N
- Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer 2:962-977, 2021
-
Tanaka Y, Chiwaki F, Kojima S, Kawazu M, Komatsu M, Ueno T, Inoue S, Sekine S, Matsusaki K, Matsushita H, Boku N, Kanai Y, Yatabe Y, Sasaki H, Mano H
- An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping. J Thorac Oncol 2021; 16: 2133-2138.
-
Teishikata T, Yatabe Y, et al.
- Reaccesssing molecular subtype of SCLC. J Thorac Oncol (Editorial) 2020; 15: 1819-1822.
-
Yasushi Yatabe
- Clinicopathologic and Molecular Characteristics of Familial Adenomatous Polyposis-associated Traditional Serrated Adenoma. Am J Surg Pathol 44:1282-1289 (2020)
-
Okamura Takuma, Hashimoto Taiki, Naka Tomoaki, Yoshida Teruhiko, Tanabe Noriko, Ogawa Reiko, Yamada Masayoshi, Saito Yutaka, Yatabe Yasushi, Sekine Shigeki
- Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol. 2019;14:377-407.
-
Yatabe Y, Dacic S, Borczuk AC, et al.
- EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res. 2015 Dec 1;21(23):5305-13.
-
Yoshihisa Kobayashi, Yosuke Togashi, Yasushi Yatabe, Hiroshi Mizuuchi, Park Jangchul, Chiaki Kondo, Masaki Shimoji, Kenichi Suda, Kenji Tomizawa, Toshiki Takemoto, Toyoaki Hida, Kazuto Nishio, Tetsuya Mitsudomi
- Comprehensive Genomic Profiles of Small Cell Lung Cancer. Nature. 2015;524:47-53.
-
George J, Lim JS, Jang SJ, Yatabe Y, Thomas RK
- Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. Ann Oncol. 2015 Jan;26(1):156-161.
-
Kobayashi Y, Mitsudomi T, Sakao Y, Yatabe Y
- Era of comprehensive cancer genome analyses. J Clin Oncol 32:4029-30, 2014 (editorial)
-
Yatabe Y, Thomas RK
- CD74-NRG1 Fusions in Lung Adenocarcinoma. Cancer Discov, 2014. 4(4): p. 415-22.
-
Fernandez-Cuesta L, Yatabe Y, Thomas R
- Surgery for NSCLC in the era of personalized medicine, Nat Rev Clin Oncol 2013, 10:235-244
-
Mitsudomi T, Suda K, Yatabe Y
- How long should small lung lesions of ground glass opacity be followed? Journal of Thoracic Oncology (2013) 8(3): 309-14.
-
Kobayashi Y, Fukui T, Ito S, Usami N, Hatooka S, Yatabe Y, Mitsudomi T
- Heterogeneous distribution of the EGFR mutation is extremely rare in lung adenocarcinoma. J Clin Oncol 2011;29:2972-7
-
Yatabe Y, Matsuo K, Mitsudomi T
- EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-9, 2010
-
Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H
- Gefitinib versus cisplatin/docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): a randomised phase III trial. Lancet Oncol 2010; 11: 121-128
-
Mitsudomi T, Morita S, Yatabe Y, et al.
- Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 2008;68:2106-11.
-
Yatabe Y, Takahashi T, Mitsudomi T